Outlook Therapeutics, Inc. entered into a securities purchase agreement for a private placement of $60 million in shares of common stock and accompanying warrants, and also entered into a registration rights agreement. They also entered into a separate securities purchase agreement with Syntone for $5 million in shares of common stock and accompanying warrants, and a registration rights agreement. Additionally, they amended a convertible promissory note with Streeterville Capital, LLC.